| Literature DB >> 26510590 |
G S Krasnov1,2,3,4, A A Dmitriev1,2, A F Sadritdinova1, N N Volchenko2, E N Slavnova2, T V Danilova2, A V Snezhkina1, N V Melnikova1, M S Fedorova1, V A Lakunina1, A A Belova1, K M Nyushko2, B Y Alekseev2, A D Kaprin2, A V Kudryavtseva1,2.
Abstract
The major problem in prostate cancer treatment is the development of drug resistance and especially important, cross-resistance. The mechanisms of drug resistance, which are divided into ligand-dependent (requiring the presence of androgens in the cell) and independent (not requiring the presence of androgens) are reviewed. The mechanisms are mainly represented with mutations of the androgen receptor and expression of aberrant constitutively active splice variants, as well as up-regulation of genes involved in androgens synthesis.Entities:
Keywords: abiraterone; androgen receptor; androgens; drug resistance; enzalutamide; mutations; prostate cancer; splice variants
Mesh：
Substances：
Year: 2015 PMID： 26510590 DOI： 10.7868/S0026898415050110
Source DB: PubMed Journal: Mol Biol (Mosk) ISSN： 0026-8984